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 Abstract  Addressing the innovation gap is today considered the third task for 
public research organizations (PROs) in addition to their traditional tasks of research 
and teaching. Thus, PROs need to adapt their strategies and research management 
organization so that more innovative ideas from research will enter the market for 
the bene fi t of society. Innovation can thus be de fi ned as value-creating novelties. 
The commercialization of research results is usually managed through technology 
transfer of fi ces (TTOs), serving as an interface to industry. How PROs create value 
is increasingly subject to performance measurement and performance-based bud-
geting. Applying holistic measures will help adjust the overall strategy of the PRO 
in the direction of innovation and balance multiple interests and goals. Holistic per-
formance measurement is based on the four dimensions of the decision-oriented 
model of research production (input, processes, output, and outcome) correspond-
ing to the pillars of innovation. In this model, patenting is a key innovation process 
in academic life sciences that arises from the co-production between researchers 
and TTOs. 
 1  Introduction 
 Creative resources in the life sciences in academic research and in industry are 
not being used ef fi ciently. This phenomenon, often described as the innovation 
gap or science-to-market gap  [ 1 ] , is very much to the detriment of the economy 
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and society. The core strategy of the European Union’s “Europe 2020” features 
the “Innovation Union” as one of seven  fl agship initiatives “to ensure that inno-
vative ideas can be turned into products and services that create growth and jobs 
 [ 2 ] .” To meet the challenges of the global knowledge society, European govern-
ments and other public funding bodies increasingly demand that public research 
organizations, including universities (together called PROs), exploit their results 
from invention and discovery through technology transfer (TT). This so-called 
“third task”—in addition to the tasks of research and teaching—enable PROs to 
capitalize more fully on public funding for the bene fi t of society. Innovations 
stemming from public research will be de fi ned in this chapter as value-creating 
novelties  [ 3 ] . 
 The commercialization activities arising out of public research are typically per-
formed by a technology transfer of fi ce (TTO). In essence, the task of a TTO is to 
 fi nd a commercial partner willing and able to develop and further test novel ideas 
into product solutions that people are willing to pay for, thereby creating value. TT 
is de fi ned by the Organization for Economic Co-operation and Development 
(OECD) as intellectual property (IP) management, whose purpose is “to identify, 
protect, exploit and defend intellectual property  [ 4 ] .” 
 The question how ef fi ciently or effectively this innovation process works has to 
be asked for the PRO as a whole. This is because it re fl ects both its output and the 
outcome of research production. To quote the old saying: “If it isn’t measured, it 
can’t be managed,” the purpose of performance measurement is thus to create trans-
parency of results and achievements, support the de fi ned strategy and decision mak-
ing, and provide guidance for behavioral change, such as integrating innovation into 
research operations. Because no indicators exist either for measuring the intangible 
results of research or for creating multidimensional outputs from research or the 
quality of interaction among the players involved, a systematic attempt will be made 
to design a  fl exible and holistic concept of performance measurement. “Holistic” 
according to  [ 5 ] incorporates:
 Focus on relevant stakeholders • 
 Balance between the resulting demands (as far as possible) • 
 Integration in a systems approach, and • 
 Sustainable and long term in orientation. • 
 2  Research Production and Innovation 
 Holistic performance measurement of TT must take into account all dimensions at 
the level of the PRO. Detailed information is needed about the causal linkages of the 
setting in which innovation occurs, the processes of innovation, and the outcome of 
innovation. 
 PROs are an essential component in the innovation chain. Faculty and research-
ers produce basic novel knowledge, some of which is inventive and patentable. 
The bulk of these inventions occur early in the discovery phase of the innovation 
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life cycle. Far from being a true product, they require additional research and 
experiments to further re fi ne and advance these early inventions and to strengthen 
the patent application prior to commercialization. Today, many TTOs have 
created and manage a gap fund to  fi nance such proof-of-concept studies to reduce 
risk and further advance their inventions in a bid to make them more attractive to 
industry. 
 One causal linkage deserves special emphasis. Patents as standard innovation 
indicators play a central role in the commercialization of life science inventions 
because only patents provide the temporary exclusivity and protection required by 
the pharmaceutical industry to recoup its huge investments in drug development. 
Thus patenting in academia deserves close scrutiny. This is because inventing and 
patenting are in fact two separate phenomena  [ 6 ] that require different strategies and 
processes. Responsibilities must be clearly allocated to ascertain who is in control 
of which part of the innovation process. 
 Usually it is the researcher’s decision to disclose their invention that triggers 
the commercialization process at the TTO. If the researcher decides only to 
publish and not to reveal the invention to the TTO, their invention will be lost 
for commercialization since it will become public knowledge and no longer be 
proprietary. Thus, failing to disclose inventions represents the  fi rst gap in the 
innovation chain. It is a myth to believe that a TT manager can just “walk the 
halls” and pick inventions like cherries that after commercial evaluation will be 
patented and successfully marketed. Researchers themselves are responsible for 
disclosing their invention to the TTO. Therefore, invention disclosures consti-
tute the only direct measure of researchers’ innovation activities. By contrast, 
the number of patents (patent applications, patents granted) re fl ects the output 
of research as a whole, including the TTO’s activities. This accords with the 
assistant role of the TTO as described in the “assisted innovation model”  [ 7 ] . 
The TTO forms both an integral part of the research production process and the 
linear innovation chain, facilitating moving inventions further along the value 
chain, thus closing the gap  [ 7 ] . 
 As patents are created as a result of the co-production between the researchers 
and their TTO, a PRO must take a twofold approach to capture the value of its 
investment in research and discovery: (1) ensure that all possible inventions are 
disclosed and (2) maintain a TTO ready and able to mine these inventions success-
fully. However, bearing in mind that the chances of meaningful commercial success 
are very low (estimated at below 1% of all invention disclosures), success can be 
de fi ned as collaborations with industry, licensing to an established company, or 
founding a spin-off. Different inputs will yield different outputs and outcomes, just 
as the ef fi ciency and effectiveness of processes will differ with expertise and experi-
ence. Although several indicators and benchmarks already exist for TT, they must 
be evaluated (holistically) at the level of the PRO. 
 The Production Model of Research : Holistic performance measures for innova-
tion from research have been developed using the decision-oriented production 
model of research  [ 8 ] . This approach has a twofold advantage. First, it makes it 
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possible to adapt performance measurement to the relevant decision-maker or 
stakeholder. Second, it is a tool to de fi ne the extent to which a PRO wishes to engage 
in innovation and take responsibility for it. The model contains four dimensions at 
the level of the PRO: input, processes, output, and outcome. These dimensions, if 
aligned sequentially, form four elements in the innovation chain (Fig.  8.1 ). 
 Input 
 Structure and resources (funding, personnel) available for research and TT, including 
the support of the commercialization process. 
 Processes 
 Research production of new knowledge includes all research activities, speci fi cally 
inventions, plus all services offered by the TTO. If inventions are not disclosed to 
the TTO, internal innovation gaps may arise, leading to an early break in the innova-
tion chain. 
 Output 
 Productivity and ef fi ciency of the PRO with respect to publications, patents, and 
commercialization results such as licensing contracts. 
 Outcome 
 The overall impact on society can be divided into institutional impact and market 
impact. Only market impact can be associated with innovation (any value generated 
such as licensing income can be reinvested in research input). 
 Fig. 8.1  Decision-oriented research production model aligned for holistic performance measure-
ment along the four elements of the innovation chain. The elements in  the top row represent the 
research elements and those in  the bottom row the commercial elements leading to innovation. 
Both must be provided with adequate resources (input) and activities (processes) to yield the 
desired output and outcome. The outcome “innovation” is only obtained by achieving market 
impact (modi fi ed according to  [ 3,  8 ] ) 
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 3  Conceptual Design of Holistic Performance Measurement 
in Technology Transfer 
 The TT process is complex in nature because it must take into consideration the 
interdependence between input, research production, TT, the various stakeholders, 
and the multiple goals of a PRO. To replicate this complexity, the conceptual design 
of performance management needs to make use of the above-mentioned decision-
oriented production model of research  [ 8 ] and should contain the following 
elements:
 Analysis of the interests of the relevant stakeholders: government, management, • 
and the researchers themselves 
 Alignment of possible goals to respective indicators • 
 Examples of evaluation methods applicable to TT • 
 3.1  Stakeholders in Technology Transfer 
 The most relevant stakeholders in the innovation process in the academic context 
are the government or other funding agencies, the PRO management, and the 
researchers themselves. Each of them will have a different interest in innovation, 
thus producing multiple, potentially con fl icting goals. 
 The Government : The government (or other public funding bodies) funds the pro-
duction of new knowledge, stipulating that funding be used sparingly and economi-
cally by maximizing desirable side effects (such as TT and international 
collaborations, equal opportunities, and promoting young researchers) and at the 
same time minimizing risks. The government might also fund speci fi c programs to 
foster innovation (such as for establishing spin-off companies). 
 Management : The PRO’s management is responsible for the overall strategy and 
budget from public money. 1 The management sets priorities and balances the multi-
ple interests of the funding bodies and other relevant interest groups. The strategy is 
often devised together with the so-called visible scientists whose expert knowledge 
constitutes the most important capital of a PRO. Managing such experts, who thrive 
on the privilege of academic freedom, is admittedly challenging. Since the research 
budget is generally decreasing rather than increasing, any change in strategy will 
result in reallocating funds, such as for those for innovation, at the expense of other 
activities. Without management’s support it might be dif fi cult to pursue commercial-
ization activities ef fi ciently. Management might also prefer short-term visible 
achievements over long-term investments in innovation. As such, management might 
 1  In the United States and Europe researchers have signi fi cant discretion in raising their own grant 
funding independently from the PRO management. 
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choose to establish collaborations with industry creating immediate research money, 
rather than investing long term in the infrastructure for TT. This is regardless of how 
small the investment is compared with research expenses. Ultimately, some PROs 
may wisely do both. 
 Faculty : Researchers and inventors certainly constitute the most important stake-
holders in innovation. It is well known that their motivation in fl uences the outcome 
of TT  [ 9,  10 ] . Researchers have three ways to convey information about their work 
results—publish, patent or do both. However, not all researchers are equally moti-
vated to patent. A researcher is primarily motivated by “solving the puzzle”  [ 6 ] , that 
is, answering scienti fi c questions not necessarily connected to patenting or com-
mercialization. Second, researchers are driven to receive recognition from their 
peers and to establish their reputation within their scienti fi c community. Third, 
money does not seem to be the primary motivation for most researchers because 
most research fails to generate patentable and commercially viable inventions. 
Therefore, although inventors usually receive a share of about 30% of the revenues 
received by the PRO, this motivation is the least powerful. This share can be sub-
stantial in a very few cases, but might take a long time to materialize due to long 
development times. 
 The propensity to disclose inventions differs among researchers. Those per-
forming basic research are less motivated to patent compared with those who 
are willing to invest additional time to validate their invention. This also holds 
true for emerging young talents who  fi rst have to build their scienti fi c reputa-
tion. In essence, researchers will be motivated to engage in commercial activi-
ties the more they feel their resulting share will be adequate in relation to the 
efforts required  [ 6 ] . Role models (and potentially feelings of envy) and the fact 
that some researchers like to “gamble” are further factors affecting researchers’ 
propensity to patent. 
 3.2  Indicators and Goals in Technology Transfer 
 Bearing the stakeholders in mind, the most visible indicator of added value from 
public research is re fl ected in the millions of dollars in licensing revenues that some 
of the large American universities receive. However, this does not automatically 
mean that these universities and their TTOs are best in class or best in process. This 
is because very few extremely successful (blockbuster) inventions can generate 
huge licensing revenues, whereas the bulk of inventions produce only a lower 
income. As a result, only 16% of TTOs in the United States operate pro fi tably, while 
more than 50% accrue losses  [ 10 ] . Moreover, licensing revenues produced by pub-
lic research constitute only a fraction of the impact and bene fi t to the economy and 
society. They re fl ect market success, which can be neither planned nor in fl uenced 
by the TTO or PRO. Using licensing revenues as the main indicator of the quality of 
the TTO or outcome of research is thus not recommended  [ 11 ] . 
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 The set of indicators from the annual Association of University Technology 
Managers (AUTM) survey represents the gold standard for measuring TTO 
performance in the United States and Canada  [ 12 ] . The survey contains a wealth of 
information collected for more than 30 years and has been expanding to include 
other continents and countries. In fact, the European Commission (EC) published a 
guideline with seven key quantitative indicators with de fi nitions matching the 
AUTM survey  [ 13 ] . For example, these allow comparison with the United States on 
a country level or benchmarking with speci fi c institutions:
 Three indicators highlight the commercial potential of public research and con-• 
stitute the output of research and the prerequisites for commercialization: (1) 
number of invention disclosures, (2) number of patent applications, and (3) num-
ber of patents granted. 
 Three indicators re fl ect the commercialization of public research by companies: • 
(4) number of new licensing agreements, (5) number of spin-offs and (6) gross 
licensing income (in Euros or dollars) and thus measure the outcome of TT. 
 In addition, one indicator was introduced that serves as a process indicator: (7) • 
the number of new collaboration agreements with industry (excluding consortia 
being funded by the EC or other public money). This makes it possible to deter-
mine the focus of the transfer activities (i.e., collaboration with industry or 
licensing). 
 Care must be taken to measure performance with indicators relevant to the 
goals and strategy of a PRO. Measuring the wrong things may subsequently lead 
innovation efforts down the wrong path. Four goals in TT are usually identi fi ed: 
service, transfer, pro fi t, and regional development. Each goal can be further bro-
ken down into strategic and operational goals and connected with one key indica-
tor as follows  [ 14 ] . 
 Service : Service for the researchers as customers means focusing on the internal 
relationships. This is done, for example, by delivering prompt service, providing 
expertise in business development in speci fi c research areas, and minimizing trans-
action times. The key indicator for service is the satisfaction survey conducted for a 
customer. Note: Because the researcher may demand services that far exceed the 
budget, satisfaction surveys could be conducted cost-effectively via a focused inter-
est group. 
 Transfer : Maximizing transfer means maximizing marketing to industry (i.e., 
e xternal relationships). For each invention the TTO assesses the most potent way of 
commercialization, giving preference to exclusive licenses and web-based click-
licensing. Researchers should be highly motivated and hand in as many invention 
disclosures as possible. The number of transferred technologies represents the key 
indicator for transfer. Note: This is a composite indicator and not so easy to assess. 
Alternatively, the number of license deals can be used as a more direct indicator. 
 Pro fi t : Maximizing pro fi t involves focusing on large markets with a high potential 
income. It is achieved, for example, by aggressively collecting royalties and pursuing 
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IP infringers. The key indicator for pro fi t is gross revenue minus direct costs. Note: 
Although this goal is pursued primarily by only 10% of the TTOs  [ 9 ] , revenues 
will always be an important measure of innovation. 
 Regional Development : Creating jobs in the region in particular is done by pro-
viding extensive coaching and teaching on how to set up a company and establish-
ing links to science parks and investors. The key indicator here is the number of 
spin-offs and the number of jobs created. Note: Universities usually have a closer 
af fi nity to their region than non-university research centers. 
 Rather than just listing the four goals, it is preferable to identify and pursue one 
primary goal  [ 14 ] . However, all of the above goals are essential to TT activities, and 
none of them can be ignored. Therefore, it is important to balance these goals and 
set priorities that can be changed from time to time if deemed necessary. Goals 1 
and 2 are both personnel-intensive, because they require extensive marketing efforts. 
Although the extent to which they are pursued might be restricted by staff and bud-
getary limitations, marketing (internal and external) needs to be continuously 
improved. 
 3.3  Evaluation Methods and Best Practices 
 The above analysis on stakeholders’ interests, goals, and indicators provides a sys-
tematic framework for holistic performance measurement. Making use of the con-
cept outlined above, a PRO will  fi rst need to design a strategy geared to innovation 
and then start measuring performance operationally. Thus, prior to evaluation, the 
expectations, purpose, and goals will be laid out and provide the necessary 
guidance. 
 Strategically, after reaching agreement on what is relevant in innovation or TT, a 
PRO will formulate its mission statement and goals or even stipulate them in its 
statues or policies. The process may well create tensions and trigger discussions on 
the importance of traditional academic values versus engaging in entrepreneurial 
activities and creating added value. However, most, if not all, PROs are subject to 
performance-based budgeting which increasingly includes patent indicators and 
other innovation measures. 
 Operationally, a PRO will need to initiate an evaluation cycle or integrate the 
performance measurement of the TT activities into its own evaluation culture and make 
use of established evaluation methods. At the Deutsches Krebsforschungszentrum 
the standard process every 5 years includes self-evaluation, benchmarking with oth-
ers, and external review. This process is described in more detail below. 
 Self-evaluation : Self-evaluation involves an analysis of the current situation, for 
example by summarizing TT results in a business report or plan, including an esti-
mate of the value of the patent portfolio and a forecast of potential licensing income. 
A SWOT analysis is a helpful tool to visualize strengths, weaknesses, opportunities 
and threats and to devise action items. 
918 Managing Life Science Innovations in Public Research...
 Benchmarking : Benchmarking compares one’s own performance with others, 
searching for the best processes, activities, and results. The aim is to learn from 
them to improve one’s own processes, activities, and results. Quantitative data are 
available from the AUTM survey. Other data may be obtained from the literature 
 [ 3,  9,  15,  16 ] . For a true comparison, the data must be standardized either with 
respect to the number of researchers potentially producing patentable results or the 
amount of research dollars received in relevant  fi elds (engineering, medicine, life 
sciences, natural sciences, computing, and so on). 
 External Evaluation : External evaluation might be conducted as a peer review on 
site. Peer review is admittedly time-consuming and has often been criticized but it 
remains the oldest and the most widely accepted qualitative tool for monitoring 
research. If done regularly in a standardized manner, such evaluation will provide a 
feedback mechanism for continuous improvement and learning. For the evaluation 
of TT activities a mixture of the following types of experts with different profes-
sional specialties should avoid creating any bias: administrative or scienti fi c direc-
tors of a PRO, directors of TT of fi ces, representatives from industry and venture 
capital and, ideally, reputable researchers with commercial experience. 
 Such external evaluation may even be performed to support management in 
devising a strategy for TT and mapping the ensuing operational steps. Management 
will traditionally include visible scientists and relevant committees. Such on-site 
peer review will result in a written expert’s opinion on topics such as (1) culture and 
ethos, including mission, self-image, internal and external outreach, (2) governance 
of the TTO, (3) business activities (IP management, collaborations with industry, 
and startup formation), (4) business development activities including gap or valida-
tion funding, (5) strategic orientation for the future, and (6) staf fi ng. 
 For holistic performance management, it is useful to formulate a set of key ques-
tions along the four dimensions of the research production model with respect to 
innovations (input, processes, output, and outcome). Table  8.1 summarizes a set of 
key questions and indicators. Moreover, these questions may be applied to create an 
innovation score card as described by Levy  [ 3 ] . 
 4  Conclusions and Recommendations 
 In summary, this chapter has detailed the elements of holistic performance measure-
ment for PROs to ful fi ll their roles of fostering, supporting, and enabling innovation 
and managing their “third task” activities. Although much has already been achieved 
there is still untapped potential for innovation from academia. Unraveling this 
potential is in fact highly complex. The decisive measurable  fi rst step for research-
ers is disclosing their inventions before publishing. The number of unreported cases 
is not known, but they constitute the innovation potential to be addressed. Patenting 
and publishing can be performed simultaneously. However, because researchers are 
under great pressure to publish their  fi ndings, there might not be enough time to 
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exemplify promising inventions prior to patenting, thus making it dif fi cult to pro-
duce strong patents for commercialization. TTOs are more directly involved in the 
innovation process and are thus a genuine organizational mechanism that closes the 
gap between invention and innovation. More still needs to be learned about the con-
sequences of introducing measures, such as performance-based budgeting. It is 
hoped—and there is reason to hope—that fostering innovation will not lead to a 
decrease in the quality of basic research. 
 Integrating innovation as a third task into any research organization requires a 
holistic approach, because innovation may be perceived as counter to the tradition 
 Table 8.1  Key questions in four dimensions to holistically measure performance and innovative 
activity of a PRO (modi fi ed from  [ 3 ] ) 
 Dimension  Key questions  Possible indicators 
 Input 
 Resources  Resources suf fi cient to create innovation? 
 Gap funding available? 
 Professional TTO available? 
 Research budget and personnel 
 TTO budget and personnel 
 Incentives 
 Strategy 
 Personnel  TTO experience suf fi cient to support 
researchers in innovation? 
 Licensing manager suf fi ciently supported 
by specialists and partners? 
 External evaluation 
 TTO structure 
 Activities 
 Service  Which services are offered by the TTO to 
the PRO and the researcher? 
 Customer satisfaction survey 
(researchers) 
 Outreach  Transparency of processes, successes, and 
activities of the TTO 
 Internal/external connectivity of the TTO? 
 Customer satisfaction survey 
(including industry) 
 Output 
 Productivity  How ef fi ciently does the TTO transfer 
input to output? 
 Ratio of patents and licenses to 
invention disclosures or per 
licensing manager 
 Yield  How ef fi ciently does the TTO produce 
results? 
 Ratio of licensing contracts per 
licensing manager 
 Time to deal 
 Licensing income minus costs 
 Outcome 
 Institutional  Which services are offered by the TTO to 
the PRO and the researcher? 
 Licensing income 
 Dependency of income on largest 
product 
 Reputation 
 Number of contacts of the TTO 
with researchers 
 Market  Transparency of processes, successes, and 
TTO activities 
 Products in the market 
 Licensing income 
 Number of spin-offs 
 Reputation 
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and culture of academic institutions. However, changes are necessary to increase 
innovation activities within a PRO for the bene fi t of society. Changes are already 
happening with novel therapeutic concepts, such as personalized or translational 
medicine. PROs have assumed responsibilities in early drug discovery formerly 
only vested with the pharmaceutical industry, such as establishing high-throughput 
screening facilities, medicinal chemistry, and early clinical trials  [ 17 ] . The key 
aspect of this public commitment is the alarmingly decreasing number of innovative 
new medicines over a period of many years. This downward trend is detrimental to 
the healthcare system and to patients  [ 18 ] . However, companies such as Genentech 
are still very successfully developing new and innovative drugs. There is reason to 
believe that their special skills in turning academia’s novel ideas into novel drugs 
constitute the key factor for success. 
 Inspired by this example, many pharmaceutical companies are now creating 
novel collaboration models with academic institutions in early drug discovery. Both 
pharmaceutical companies and academia are striving to overcome cultural and orga-
nizational barriers and boundaries between them and thus are becoming more 
 fl exible in interacting with one another. Learning to integrate the best of both worlds 
seems like a promising way to create added value. For example, the collaborative 
innovation alliance between the Deutsches Krebsforschungszentrum and Bayer 
Healthcare can be highlighted where joint projects are performed together along 
de fi ned milestones, directly feeding successful projects into the internal Bayer pipe-
line. This risk-and-reward sharing partnership model is based on interactions at all 
organizational levels in an open and mutually bene fi cial atmosphere of an exchange 
of ideas  [ 19 ] . In a few years’ time the ultimate measure of success of such academic 
institutions and industry alliances will be the introduction of innovative treatments 
into patient care. 
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